Effect of intravitreal conbercept injection on VEGF‑A and ‑B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy

Zhang,Yunda; Gao,Zhao; Zhang,Ximei; Yuan,Zhigang; Ma,Tao; Li,Gaiyun; Gao,Xiaohong

doi:10.3892/etm.2021.9763

Effect of intravitreal conbercept injection on VEGF‑A and ‑B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy

Authors:
- Yunda Zhang
- Zhao Gao
- Ximei Zhang
- Zhigang Yuan
- Tao Ma
- Gaiyun Li
- Xiaohong Gao
View Affiliations

Affiliations: Department of Vitreoretinopathy, Shanxi Eye Hospital, Taiyuan, Shanxi 030002, P.R. China
Published online on: February 8, 2021 https://doi.org/10.3892/etm.2021.9763
Article Number: 332
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the mechanisms of anti‑VEGF treatment prior to eye surgery to reduce intraoperative bleeding. A total of 30 patients with proliferative vitreoretinopathy after clinical diagnosis were enrolled in the present study as the surgical group. Furthermore, 30 patients underwent intravitreal injection of the anti‑VEGF drug conbercept and were considered the drug pretreatment group. The aqueous and vitreous humors from the eyes of patients in the surgical group were drawn during pars plana vitrectomy surgery. The aqueous humor in the eyes of patients in the drug pretreatment group was drawn prior to conbercept treatment and seven days after conbercept treatment immediately prior to surgery. The vitreous humor in this group was only taken during surgery. Furthermore, ELISA was used to detect the levels of VEGF‑A and ‑B in the aqueous and vitreous humors. Semi‑quantitative determination of VEGF‑A and VEGF‑B levels in fibrovascular proliferative membranes was performed using immunohistochemical staining. The results indicated that in the drug group, the levels of VEGF‑A in the aqueous humor of patients prior to and after conbercept injection were 197.66±48.00 and 3.39±2.54 pg/ml, respectively. The levels of VEGF‑A in the vitreous humor of patients in the surgical and drug groups were 267.53±179.60 and 21.43±5.81 pg/ml after injection, respectively. The levels of VEGF‑B in the aqueous humor of patients prior to and after conbercept injection were 13.66±3.30 (before injection) and 2.17±0.94 pg/ml (after injection), respectively. The levels of VEGF‑B in the vitreous humor of patients in the surgical and drug groups were 127.36±16.72 and 18.56±9.82 pg/ml after injection, respectively (P<0.05). Furthermore, in the drug group, the surgery time, bleeding and capillary formation were significantly reduced compared with those in the surgical group. Taken together, these results suggested that the levels of VEGF‑A and ‑B decreased significantly in the aqueous humor of patients with PDR after conbercept injection. Furthermore, the levels of VEGF‑A and ‑B in the vitreous humor of patients dropped significantly in the drug group compared with those in the surgical group. These results provide theoretical clinical support for the preoperative application of conbercept for patients with PDR.

View Figures

View References

1	Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, Ghaznavi H and Naseripour M: Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 193:20–33. 2018.PubMed/NCBI View Article : Google Scholar
2	Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al: Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 35:556–564. 2012.PubMed/NCBI View Article : Google Scholar
3	Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, et al: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 110:1677–1682. 2003.PubMed/NCBI View Article : Google Scholar
4	Hershberger VS, Augsburger JJ, Hutchins RK, Raymond LA and Krug S: Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: Ultrasound biomicroscopy findings. Ophthalmology. 111:1215–1221. 2004.PubMed/NCBI View Article : Google Scholar
5	Lang GE: Diabetic macular edema. Ophthalmologica. 227 (Suppl 1):S21–S29. 2012.PubMed/NCBI View Article : Google Scholar
6	Waisbourd M, Goldstein M and Loewenstein A: Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol. 89:203–207. 2011.PubMed/NCBI View Article : Google Scholar
7	Nicholson BP and Schachat AP: A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 248:915–930. 2010.PubMed/NCBI View Article : Google Scholar
8	Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, et al: Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 122:2044–2052. 2015.PubMed/NCBI View Article : Google Scholar
9	Ciulla TA, Amador AG and Zinman B: Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies. Diabetes Care. 26:2653–2664. 2003.PubMed/NCBI View Article : Google Scholar
10	Grauslund J, Green A and Sjolie AK: Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia. 52:1829–1835. 2009.PubMed/NCBI View Article : Google Scholar
11	Yang X, Xu J, Wang R, Mei Y, Lei H, Liu J, Zhang T and Zhao H: A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy. J Ophthalmol. 2016(2473234)2016.PubMed/NCBI View Article : Google Scholar
12	Tetikoglu M, Yuksel Z, Aktas S, Sagdik HM and Ozcura F: VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. Int Ophthalmol. 38:2381–2388. 2018.PubMed/NCBI View Article : Google Scholar
13	Mesquita J, Castro de Sousa J, Vaz-Pereira S, Neves A, Tavares-Ratado P, M Santos F, A Passarinha L and T Tomaz C: VEGF-B levels in the vitreous of diabetic and non-diabetic patients with ocular diseases and its correlation with structural parameters. Med Sci (Basel). 5(17)2017.PubMed/NCBI View Article : Google Scholar
14	Ahn J, Woo SJ, Chung H and Park KH: The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 118:2218–2226. 2011.PubMed/NCBI View Article : Google Scholar
15	Yeh PT, Yang CM, Lin YC, Chen MS and Yang CH: Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 29:768–774. 2009.PubMed/NCBI View Article : Google Scholar
16	Pan GD, Yang JQ, Yan LN, Chu GP, Liu Q, Xiao Y and Yuan L: Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol. 15:431–440. 2009.PubMed/NCBI View Article : Google Scholar
17	Takahashi S: Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011.PubMed/NCBI View Article : Google Scholar
18	Yang CM, Yeh PT, Yang CH and Chen MS: Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol. 146:211–217. 2008.PubMed/NCBI View Article : Google Scholar
19	Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.PubMed/NCBI View Article : Google Scholar
20	Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N and Adamis AP: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 114:964–970. 1996.PubMed/NCBI View Article : Google Scholar
21	Ferrone PJ and Jonisch J: Comparison of ranibizumab 0.5 mg versus 1.0 mg for the treatment of patients with clinically significant diabetic macular edema: A randomized, clinical trial. Ophthalmic Surg Lasers Imaging Retina. 47:536–543. 2016.PubMed/NCBI View Article : Google Scholar
22	Dong F, Yu C, Ding H, Shen L and Lou D: Evaluation of intravitreal ranibizumab on the surgical outcome for diabetic retinopathy with tractional retinal detachment. Medicine (Baltimore). 95(e2731)2016.PubMed/NCBI View Article : Google Scholar
23	Arevalo JF, Lasave AF, Kozak I, Al Rashaed S, Al Kahtani E, Maia M, Farah ME, Cutolo C, Brito M, Osorio C, et al: Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: A prospective randomized clinical trial. Am J Ophthalmol. 207:279–287. 2019.PubMed/NCBI View Article : Google Scholar
24	Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L, et al: VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA. 106:6152–6157. 2009.PubMed/NCBI View Article : Google Scholar
25	Zhong X, Huang H, Shen J, Zacchigna S, Zentilin L, Giacca M and Vinores SA: Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol Vis. 17:492–507. 2011.PubMed/NCBI
26	Puddu A, Sanguineti R, Traverso CE, Viviani GL and Nicolo M: Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro. Eur J Ophthalmol. 26:425–430. 2016.PubMed/NCBI View Article : Google Scholar
27	Puddu A, Sanguineti R, Traverso CE, Viviani GL and Nicolo M: Response to anti-VEGF-A treatment of endothelial cells in vitro. Exp Eye Res. 146:128–136. 2016.PubMed/NCBI View Article : Google Scholar
28	Wafai R, Tudor EM, Angus JA and Wright CE: Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind limb ischemia. J Vasc Res. 46:45–54. 2009.PubMed/NCBI View Article : Google Scholar
29	Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, et al: VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 92:1098–1106. 2003.PubMed/NCBI View Article : Google Scholar
30	Zhang X, Wu J, Wu C, Bian AL, Geng S and Dai RP: Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection. Diabetes Res Clin Pract. 162(108083)2020.PubMed/NCBI View Article : Google Scholar
31	Torres-Soriano ME, Reyna-Castelan E, Herna´ndez-Rojas M, Garcıa-Aguirre G, Kon-Jara V, Diaz-Rubio JL, Guerrero-Naranjo JL, Jimenez-Sierra JM and Quiroz-Mercado H: Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy. Retin Cases Brief Rep. 3:70–73. 2009.PubMed/NCBI View Article : Google Scholar
32	Simo R, Sundstrom JM and Antonetti DA: Ocular Anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 37:893–899. 2014.PubMed/NCBI View Article : Google Scholar
33	Spilsbury K, Garrett KL, Shen WY, Constable IJ and Rakoczy PE: Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 157:135–144. 2000.PubMed/NCBI View Article : Google Scholar